NETVISION DIN 02525542
Health Canada record
| Active ingredient(s) | GALLIUM 68 Ga OXODOTREOTIDE 122 MBq |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09IX OTHER DIAGNOSTIC RADIOPHARM. FOR TUMOR DETECTION |
| Original market date | 03-May-2023 |
| Current status date | 01-Jan-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
University Health Network Radiotheranostics Core — licence 3-002814, not currently licensed, last inspection rating C (2023-09-11).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30385 | 2023-03-21 | New Drug Submission (NDS) | Administrative ¿ Change in Product Ownership |
| 27664 | 2022-02-24 | New Drug Submission (NDS) |